Re-exposure of a PD-1 inhibitor after previous immune-related adverse events
Background: Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
24 March 2026
|
| In: |
Current oncology
Year: 2026, Volume: 33, Fascicolo: 4, Pages: 1-12 |
| ISSN: | 1718-7729 |
| DOI: | 10.3390/curroncol33040180 |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/curroncol33040180 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1718-7729/33/4/180 
|
| Note sull'autore: | Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, Joanna Mangana, Deniz Özistanbullu, Johannes Kleemann, Alexander Enk and Jessica C. Hassel |
| Riassunto: | Background: Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of interest to determine whether readministration of another or the same PD-(L)1 inhibitor is safe. Methods: This is a multicenter, retrospective study on patients with metastasized dermatological tumors who were retreated with either the same or a different PD-(L)1 inhibitor after the development of irAEs. The study was conducted at centers in Heidelberg, Zurich, and Frankfurt. Results: 22 patients were included between April 2020 and December 2022 with a median age of 71 years. A total of 13 (59%) patients were re-exposed with the same antibody and nine (41%) received a different PD-(L)1 inhibitor. Six (46%) of the patients who were re-exposed to the same antibody had an irAE, of which 67% were identical with the first. In patients receiving a different PD-(L)1 inhibitor, four (44%) developed an irAE, of which 75% were identical with the first. Conclusions: Both an intraclass switch of PD-(L)1 inhibitor treatment and re-exposure with the same antibody after an irAE can be considered as options with a fair chance of improving therapy tolerance. |
|---|---|
| Descrizione del documento: | Veröffentlicht: 24. März 2026 Gesehen am 10.06.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1718-7729 |
| DOI: | 10.3390/curroncol33040180 |